Company intelligence / Profile preview

Nosis Bio

Berkeley, California, United Statesnosisbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Nosis Bio has developed a proprietary AI-enabled platform called Connexa for designing receptor-targeted RNA therapeutics. The company focuses on overcoming the challenge of cell-specific delivery in RNA medicines and aims to unlock gene silencing therapies for a wide range of chronic diseases. No clinical results have been published yet; the company is actively partnering with major pharma companies.

Therapeutic areas: OncologyRare Diseases
Modalities: RNA therapeutics (gene silencing)Cell-targeted delivery vehicles
Industry: Biotech

Partnerships

Daiichi Sankyo – research collaboration and option agreement for cell-targeted RNA medicinesJohnson & Johnson – strategic collaboration for design/development of cell-targeted delivery vehicles

Beyond the preview

Go deeper on Nosis Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nosis Bio.

Explore the full profile